AllianceBernstein
PHAT icon

AllianceBernstein’s Phathom Pharmaceuticals PHAT Stock Holding History

AllianceBernstein’s Portfolio PHAT Stock Details PHAT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$548K Sell
49,290
-100
-0.2% -$1.14K ﹤0.01% 2656
2026
Q1 		$819K Hold
49,390
– – ﹤0.01% 2424
2025
Q4 		$819K Buy
49,390
+3,800
+8% +$54.3K ﹤0.01% 2434
2025
Q3 		$537K Sell
45,590
-5,000
-10% -$51.6K ﹤0.01% 2637
2025
Q2 		$485K Buy
50,590
+5,000
+11% +$27.7K ﹤0.01% 2653
2025
Q1 		$286K Hold
45,590
– – ﹤0.01% 2794
2024
Q4 		$370K Sell
45,590
-4,520
-9% -$56K ﹤0.01% 2776
2024
Q3 		$906K Hold
50,110
– – ﹤0.01% 2370
2024
Q2 		$516K Buy
50,110
+17,820
+55% +$184K ﹤0.01% 2653
2024
Q1 		$343K Sell
32,290
-5,410
-14% -$45.9K ﹤0.01% 2758
2023
Q4 		$344K Hold
37,700
– – ﹤0.01% 2782
2023
Q3 		$391K Hold
37,700
– – ﹤0.01% 2697
2023
Q2 		$540K Buy
37,700
+10,400
+38% +$120K ﹤0.01% 2595
2023
Q1 		$195K Buy
27,300
+4,800
+21% +$42.2K ﹤0.01% 2914
2022
Q4 		$252K Buy
22,500
+6,700
+42% +$69.1K ﹤0.01% 2924
2022
Q3 		$175K Buy
15,800
+1,200
+8% +$11.4K ﹤0.01% 3047
2022
Q2 		$123K Buy
14,600
+2,900
+25% +$29.8K ﹤0.01% 3102
2022
Q1 		$159K Sell
11,700
-1,200
-9% -$19.4K ﹤0.01% 3041
2021
Q4 		$254K Buy
12,900
+1,900
+17% +$44.7K ﹤0.01% 2994
2021
Q3 		$353K Sell
11,000
-1,300
-11% -$43.2K ﹤0.01% 2904
2021
Q2 		$416K Buy
12,300
+1,800
+17% +$64.5K ﹤0.01% 2891
2021
Q1 		$394K Sell
10,500
-900
-8% -$37.7K ﹤0.01% 2778
2020
Q4 		$379K Sell
11,400
-700
-6% -$28.4K ﹤0.01% 2733
2020
Q3 		$444K Sell
12,100
-1,900
-14% -$65.8K ﹤0.01% 2580
2020
Q2 		$461K Buy
+14,000
New +$538K ﹤0.01% 2666

Other funds holding PHAT

FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $177M AUM 212.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10B AUM 10.61% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
GKIM
GW&K Investment Management Boston, Massachusetts $12.8B AUM 48.82% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

AllianceBernstein's PHAT Position: Q2 2026 in Review

AllianceBernstein reduced its Phathom Pharmaceuticals (PHAT) stake by 0.2% in Q2 2026, selling an estimated $1.14K and leaving 49,290 shares worth $548K. The position accounts for ﹤0.01% of the portfolio, ranked #2656.

AllianceBernstein first reported a position in PHAT in Q2 2020 and has held it in 25 quarters since. The position peaked at $906K in Q3 2024. 162 funds tracked by Wall St. Rank hold PHAT as of Q2 2026.

  • AllianceBernstein held 49,290 shares of Phathom Pharmaceuticals worth $548K as of Q2 2026.
  • AllianceBernstein sold 100 Phathom Pharmaceuticals shares in Q2 2026, an estimated $1.14K.
  • Phathom Pharmaceuticals made up ﹤0.01% of AllianceBernstein's portfolio in Q2 2026, its #2656 holding.
  • AllianceBernstein first reported a position in Phathom Pharmaceuticals in Q2 2020 and has held it in 25 quarters since.
  • AllianceBernstein's Phathom Pharmaceuticals position peaked at $906K in Q3 2024.
  • 162 funds tracked by Wall St. Rank held Phathom Pharmaceuticals as of Q2 2026.

Based on AllianceBernstein's 13F filing for Q2 2026, filed 14 Aug 2026.